The multicenter, single-arm DOLPHIN phase II trial (ID: jRCT2080224763) demonstrated an objective response rate (ORR) of 90.9% (95% CI, 75.7%–98.1%) when the PD-L1 inhibitor durvalumab was combined with curative RT in patients with unresectable, PD-L1-positive, locally advanced NSCLC [92]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.